膀胱がん治療薬の世界市場

膀胱がん治療薬の世界市場は2030年までに3億4,530万米ドルに達する見込み

2023年に2億5,500万米ドルと推定された膀胱がん治療薬の世界市場は、2030年には3億4,530万米ドルに達し、分析期間2023-2030年のCAGRは4.4%で成長すると予測されます。Transitional Cell 膀胱がん治療薬は、本レポートで分析したセグメントの1つであり、CAGR 3.9％を記録し、分析期間終了時には1億1,460万米ドルに達すると予測されています。非筋肉侵襲性／表在性膀胱がん治療薬セグメントの成長率は、分析期間中CAGR 5.2％と推定されます。

米国市場は6,890万米ドルと推定、中国はCAGR 7.3％で成長予測

米国の膀胱がん治療薬市場は、2023年に6,890万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.3%で成長し、2030年には7,220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.3％と3.6％と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の膀胱がん治療市場- 主要動向と促進要因のまとめ

膀胱がん（BCa）は、泌尿器系で最も有病率が高く、経済的にも負担の大きい悪性腫瘍の1つとして認識されており、再発率と進行率が高いことが指摘されています。膀胱がん治療薬の市場は、人口統計学的、技術的、臨床的要因の組み合わせによって牽引されています。多くのがんと同様に、膀胱がんの治療法の開発と改良は、現在進行中の研究発見、検診の増加、高齢化によって影響を受けます。膀胱がん治療薬市場の主な促進要因は、世界の罹患率の上昇です。人口の高齢化、特定の化学物質への曝露、喫煙、その他のライフスタイルのリスクなどの要因が、膀胱がんの症例数の増加に寄与しています。この増加は当然、効果的な治療に対する需要を促進します。有望な膀胱がん治療薬に対するファスト・トラック指定や承認など、政府の支援政策が技術革新を促し、市場での新薬の利用を促進しています。さらに、官民双方からのがん研究への資金援助が世界的に増加し、新たな治療法の開発が促進されています。

膀胱がんの治療と管理は、学際的研究と技術革新に後押しされ、特に診断と治療アプローチにおいて著しい進歩を遂げています。標的治療、免疫療法、非侵襲的診断バイオマーカーにおける最近の動向は有望であり、より個別化された効果的で侵襲の少ない治療選択肢につながる可能性があります。さらに、分子診断や画像診断などの診断技術の進歩は、早期発見と正確な病期分類に不可欠であり、これらは効果的な治療と患者の予後改善に不可欠です。尿中バイオマーカーの開発は、より侵襲性の低い診断選択肢を提供するが、臨床への普及は依然として困難であり、さらなる検証が必要です。

製薬業界とバイオテクノロジー業界は、進行期や治療抵抗性のBCa患者に新たな希望を与える革新的な標的治療薬や免疫療法など、新規治療薬の開発を積極的に進めています。膀胱がん治療では、バイオマーカーや遺伝子配列を利用して個々の患者のプロファイルに合わせた治療を行い、有効性を最適化し副作用を最小限に抑える個別化医療が大きなトレンドとなっています。この分野が進化を続ける中、診断におけるディープラーニングとAIの統合は、併用療法やがんナノメディシンの進行中の研究と相まって、より洗練された、効果的な、患者中心の治療戦略へのダイナミックなシフトを強調しています。

調査対象企業の例（注目の全62社）

• AstraZeneca plc
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bladder Cancer Therapeutics Market to Reach US$345.3 Million by 2030

The global market for Bladder Cancer Therapeutics estimated at US$255.0 Million in the year 2023, is expected to reach US$345.3 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Transitional Cell Bladder Cancer Therapeutics, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$114.6 Million by the end of the analysis period. Growth in the Non Muscle Invasive / Superficial Bladder Cancer Therapeutics segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.9 Million While China is Forecast to Grow at 7.3% CAGR

The Bladder Cancer Therapeutics market in the U.S. is estimated at US$68.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$72.2 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Bladder Cancer Therapeutic Market - Key Trends and Drivers Summarized

Bladder cancer (BCa) is recognized as one of the most prevalent and financially burdensome malignancies of the urinary system, noted for its high rates of recurrence and progression.  The market for bladder cancer therapeutics is driven by a combination of demographic, technological, and clinical factors.  As with many forms of cancer, the development and refinement of treatments for bladder cancer are influenced by ongoing research discoveries, increased screening, and an aging population. The primary driver for the bladder cancer therapeutics market is the rising incidence of the disease globally. Factors such as aging populations, exposure to certain chemicals and smoking, and other lifestyle risks contribute to the growing number of bladder cancer cases. This increase naturally drives demand for effective treatments. Supportive government policies, including fast-track designations and approvals for promising bladder cancer treatments, encourage innovation and expedite the availability of new drugs in the market. Additionally, increased funding for cancer research from both public and private sectors globally enhances the development of new therapeutic options.

The treatment and management of bladder cancer are undergoing significant advancements, particularly in diagnostic and therapeutic approaches, fueled by interdisciplinary research and technological innovations. Recent developments in targeted therapies, immunotherapy, and non-invasive diagnostic biomarkers are promising, potentially leading to more personalized, effective, and less invasive treatment options. Furthermore, advancements in diagnostic technologies such as molecular diagnostics and imaging techniques are crucial for early detection and accurate staging, which are essential for effective treatment and improved patient outcomes. The development of urinary biomarkers offers a less invasive diagnostic alternative, though widespread clinical integration remains challenging and necessitates further validation.

The pharmaceutical and biotechnology sectors are actively pursuing the development of novel therapeutics for BCa, including innovative targeted therapies and immunotherapies that provide new hope for patients with advanced-stage or treatment-resistant forms of the disease. There is a significant trend towards personalized medicine in bladder cancer treatment, utilizing biomarkers and genetic sequencing to tailor treatments to individual patient profiles, optimizing efficacy and minimizing side effects. As the field continues to evolve, the integration of deep learning and AI in diagnostics, coupled with ongoing research into combination therapies and cancer nanomedicine, underscores a dynamic shift towards more sophisticated, effective, and patient-centered treatment strategies.

Select Competitors (Total 62 Featured) -

• AstraZeneca plc
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Bladder Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Bladder Cancer Drives Therapeutics Market Growth
  • Growth in Geriatric Population Strengthens Business Case for Bladder Cancer Therapeutics
  • Integration of Personalized Medicine in Cancer Treatment Throws Spotlight on Innovation
  • Advances in Targeted Therapy Propel Market Development
  • Rising Investments in Cancer Immunotherapy Expands Market Horizons
  • Growing Focus on Early Diagnosis and Treatment Spurs Adoption of Bladder Cancer Therapeutics
  • Rising Demand for Combination Therapies in Bladder Cancer. Here is the Story
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Bladder Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Transitional Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Transitional Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Transitional Cell Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Squamous Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Squamous Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Squamous Cell Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Other Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Other Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Other Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 34: World Bladder Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• JAPAN
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• CHINA
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• EUROPE
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Bladder Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• FRANCE
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: France 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: France 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• GERMANY
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Germany 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Italy 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: UK 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Spain 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Russia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Rest of Europe 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: Australia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• INDIA
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: India 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: India 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: South Korea 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Bladder Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Argentina 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Brazil 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Mexico 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Rest of Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Bladder Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Iran 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Israel 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Saudi Arabia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: UAE 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Rest of Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
• AFRICA
  • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 220: Africa 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030

IV. COMPETITION